Source | Cyber blue
Edit | color
In the last three months, a large number of drugs will not be reimbursed in many provinces
01
The countdown is coming, and a large number of medicines will no longer be reimbursed
Recently, the Beijing Municipal Medical Insurance Bureau issued the "Notice on Announcing the Second Batch of Drug Varieties and Standardized Drug Names of Non-National Medical Insurance Drug Catalogs in the City".
The notice shows that from December 1, 2021, 182 non-national medical insurance drug catalogue varieties such as "atropine promethazine injection" will be deleted from the city's medical insurance drug catalog, and the names and dosage forms of 48 drugs such as "Qingkailing injection" will be standardized and adjusted.
That is to say, there are less than two months to go before a batch of drugs will be transferred out of the Beijing Municipal Medical Insurance Directory.
According to Cyberland, January 1, 2022 is an important time point for multi-provincial drugs to transfer out of medical insurance, at that time, a large number of drugs will no longer be reimbursed.
Guizhou(339)
On August 3, the Guizhou Medical Insurance Bureau and the Guizhou Human Resources and Social Security Department issued the "Notice on Transferring Some Drugs out of the Catalogue of Drugs for Work Injury Insurance and Maternity Insurance in Guizhou Province (2021)", saying that from January 1, 2022, 339 drugs such as sidi iodine will be transferred out of the Drug Catalogue. Before the above-mentioned drugs are transferred, they shall continue to be paid in accordance with the relevant provisions of the Drug List.
Shaanxi(63)
Previously, the Shaanxi Provincial Medical Insurance Bureau issued a public announcement on transferring some drugs out of the payment scope of basic medical insurance, and after expert argumentation, the list of the first batch of digestion drugs in Shaanxi Province was determined, and the payment scope of the Shaanxi Provincial Medical Insurance Fund was excluded from January 1, 2021.
Qinghai(129)
Previously, the Qinghai Provincial Medical Insurance Bureau issued the Notice on Printing and Distributing the Supplementary Drug Digestion Catalogue of Qinghai Province. The notice shows that in 2020, a total of 129 varieties of drugs that were not recruited and used by the national key monitoring drugs and the drug procurement platform of Qinghai Province in the previous year were transferred, and medical insurance and work injury insurance reports were stopped from January 1, 2021.
Zhejiang(118)
On August 3, the Zhejiang Medical Insurance Bureau and the Zhejiang Department of Human Resources and Social Security issued the "Notice on Transferring Some Drugs out of the Catalogue of Drugs for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance in Zhejiang Province", which requires that from January 1, 2022, 118 drugs such as amoxicillin dicloxacillin be transferred out of the Zhejiang Provincial Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue.
Sichuan(145)
On July 26, the Sichuan Medical Insurance Bureau issued the "Notice on Further Improving the Digestion of Class B Drugs in the Province's Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (Draft for Comment)" that after expert argumentation, the Sichuan Provincial Medical Insurance Bureau decided to transfer 145 drugs such as butyl boron ointment out of the payment scope of Sichuan Province's basic medical insurance, work injury insurance and maternity insurance from January 1, 2022.
Jiangsu(156)
On July 14, the Jiangsu Provincial Medical Insurance Bureau issued the "Notice of the Department of Human Resources and Social Security of Jiangsu Province on Publishing the Second Batch of Supplementary Drugs in the Catalogue of Basic Medical Insurance, Work Injury Insurance and Maternity Insurance", showing:
Provincial medical insurance agencies should promptly do a good job in maintaining the information of the basic medical insurance, work injury insurance and maternity insurance drug catalog database in Jiangsu Province, and transfer out all varieties under the generic name of the second batch of digestion drugs involved. At the same time, all drugs that were originally maintained under the generic name of the drug and did not comply with the current generic name rules were transferred out synchronously.
At the same time, Jiangsu Province announced that from January 1, 2022, all the costs incurred for transferred drugs will no longer be included in the payment scope of Jiangsu Province's basic medical insurance, work injury insurance and maternity insurance funds.
Chongqing Municipality
According to the arrangement of the Chongqing Medical Insurance Bureau, Chongqing local medical insurance digests drugs in the second year and stops medical insurance reimbursement from January 1, 2022. The second year digestion medicines are as follows:
Ampicillin probenecid (oral common-release dosage form, the drug has been renamed "ampicillin probene"),flucloxacillin (injectable), cefazolin pentahydrate (injection), cefloxime (injection), ceftriaxazotazol (injection), ceftriaxonazol (injection), cefotali (injection), roxithromycin (extended-release controlled-release dosage form), persemin (injection), clozoxazone (oral regular-release dosage form), gauuroxabrin (injection), compound amino acids (8-11) (oral common-release form), deoxynucleotide (injection), Compound amino acids (15) dipeptides (2) (injectables), long-chain fatty milk (OO) (injections), BCG polysaccharides (injections), pitolimod (oral regular-release dosage forms), placental polypeptides (injections), paclitaxel liposomes (injections), recombinant modified human tumor necrosis factor (injections), vinblastamine (extended-release controlled-release dosage forms), snake enzymes (injections), gustil (injections), meclofentil (injections), acetyl gastroestrin (oral regular-release dosage forms), ambroxol (extended-release controlled-release dosage forms), Cocodeine (oral liquid), cisapride (oral regular-release dosage form), matrine (oral regular-release dosage form), ornithine aspartate (granules), ginseng glucose (injectable), coenzyme Q10 (oral regular-release dosage form), levocarnitine (oral liquid), mannan peptide (injection), fructose sodium diphosphate (oral liquid), low molecular weight dextran amino acid (injection), compound electrolyte (injection), sodium potassium magnesium calcium glucose (injection), aminoiodide (eye drops), Three-dimensional mycin (suppository), intestinal laxative capsules, QianLian tablets (granules, capsules), Monkey Earrings anti-inflammatory tablets, sub-leaf bead capsules (tablets), Shalian and stomach capsules, Mustang Chase syrup, anti-brain failure capsules, yi brain heart granules, Wuzi Yanzong oral liquid (pills, tablets, soft capsules), Schizandra syrup (capsules, tablets, granules), compound Fufang Vine Combination (capsules), compound Da Hong Pao hemostatic capsules, Hekang oral liquid (granules), hemostatic treasure granules, cardiomyoplast injection, blood house stasis soft capsules, danshen for injection, Safflower Yellow Pigment for Injection, Yixinone Tablets (Capsules), Haidan Capsules, St. John's Wort Extract Tablets, Agarwood Gas Pills (Capsules), Saw palmetite Fruit Extract Softgels, Lipid-Lowering Tongluo Softgels, Stone-Killing Choleretic Capsules, Musk Shu Huo ling, Toad Crisp Injection, Jin throat Pills, Zhenhuang Pills, Dusheng Huo Blood Tablets, Calendula Dispersible Tablets, Shu Liver And Spleen Granules, Entacapone Double Dopa Tablets (II.) (Tablets, Beijing Novartis Pharmaceutical Co., Ltd.), Pioglitazone Metformin Tablets (Tablets, Hangzhou Sino-American Huadong Pharmaceutical Co., Ltd., Jiangsu Deyuan Pharmaceutical Co., Ltd.), Ratanthimo Eye Drops (Eye Drops, Pfizer Manufacturing Belgium NV), Mixed Sugar Electrolyte Injection (Injection, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.), Peridole Indapamide Tablets (Tablets, Svea (Tianjin) Pharmaceutical Co., Ltd.), Fat Milk Amino Acids (18) Injection (Injection, Sichuan Kelun Pharmaceutical Co., Ltd.), Estradiol/Estradiol Didrogestrol Tablets Composite Packaging (Tablets, Tablets, Abbott Biologicals B.V.), Oshali Platinum Mannitol Injection (Injection, Sichuan Meida Kangjiale Pharmaceutical Co., Ltd., Chenxin Pharmaceutical Co., Ltd.), Fat-Soluble Vitamins for Injection (II.)/Water-Soluble Vitamins for Injection Package (Injection, Chengdu Tiantaishan Pharmaceutical Co., Ltd., Hebei Zhitong Biopharmaceutical Co., Ltd.), Kandi Hydrodi tablets (tablets, Jiangsu Deyuan Pharmaceutical Co., Ltd.), Compound Vitamins for Injection (3) (Injections, Liaoning Haisco Pharmaceutical Co., Ltd.), Omeprazole Sodium Bicarbonate Capsules (capsules, Xiamen Encheng Pharmaceutical Co., Ltd.), Diclofenac sodium lidocaine for injection (injection (lyophilized powder injection), Beijing Sihuan Kebao Pharmaceutical Co., Ltd.), Apricot Root Sodium Chloride Injection (Injection, Honghe Pharmaceutical (China) Co., Ltd.), Multiple Oil and Fat Emulsion Injection (C6-24) (Injection, Fresenius Kabi Austria GmbH), Compound Brain Peptide Ganglioside Injection (Injection). , Jilin Buchang Pharmaceutical Co., Ltd., the manufacturer changed its name to Jilin Tiancheng Pharmaceutical Co., Ltd.), compound astryptide injection (injection, Jilin Buchang Pharmaceutical Co., Ltd., the manufacturer changed its name to Jilin Tiancheng Pharmaceutical Co., Ltd.), Qufu Timo eye drops (eye drops, s.a. ALCON-COUVREUR n.v.), ambrobrobuterol oral solution (oral solution, Beijing Hanmei Pharmaceutical Co., Ltd.), 12 multivitamins for injection (injection, the drug has been renamed " Multivitamins for Injection (12)", Shanxi Pude Pharmaceutical Co., Ltd.), Compound Diclofenac Sodium Injection (Injection, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.), Alendronate Sodium Vitamin D3 Tablets (II.) (Tablets, Hangzhou Merck & Co., Ltd.), Clindamycin Glucose Injection (Injection), Ambroxol Hydrochloride Glucose Injection (Injection), Granisetron Hydrochloride Glucose Injection (Injection), Doxofylline Glucose Injection (Injection), Ozagire sodium glucose injection (injection), bromohexenazine hydrochloride injection (injection), clindamycin sodium chloride injection (injection), ambroxol hydrochloride sodium chloride injection (injection), famotetin sodium chloride injection (injection), todan setron hydrochloride sodium chloride injection (injection), potassium chloride chloride injection (injection), nicardipine hydrochloride sodium chloride injection (injection), Ozagrel sodium chloride injection (injection), Piracetam sodium chloride injection (injection) , ofloxacin sodium chloride injection (injection), betaxestine hydrochloride sodium chloride injection (injection), morphinonidazole sodium chloride injection (injection)
02
A nationwide unified medical insurance catalogue in 2022
On September 29, the General Office of the State Council released the 14th Five-Year Plan for Universal Medical Security, an important programmatic document for medical insurance work in the next few years.
The plan is clear, and we will continue to carry out key tasks such as unifying the medical insurance catalogue nationwide in 2022 and dynamically adjusting the medical insurance drug catalogue.
In 2022, the scope of basic medical insurance in the country will be basically unified. Establish and improve the payment standards for medical insurance drugs, starting from negotiating drugs, centralized procurement of drugs and payment standards for patients with "two diseases", and gradually connecting the management and payment standards of medical insurance drug catalogs.
Up to now, more than 20 provinces such as Gansu, Ningxia, Xinjiang, Guangxi, Zhejiang, Shaanxi, Yunnan, Hunan, Jilin, Tianjin, Hebei, Anhui, Tibet, Beijing, Chongqing, Jiangsu, Qinghai, Chongqing, Sichuan, henan and other provinces have implemented the policy of transferring local supplementary catalogues.
It is worth noting that although a large number of drugs will be transferred, in the process of expert review, replaceability has been used as an important indicator, that is, there are drugs with comparable or better efficacy in the list of drugs that are transferred to be substituted.
At the same time, the transfer of these drugs is actually to make room for more new drugs and good drugs to be included in the catalog.
The "14th Five-Year Plan" for National Medical Security also pointed out that it is necessary to improve the adjustment mechanism of the medical insurance drug list. Based on the affordability of the fund, to meet the basic medical needs of the masses and the needs of clinical technological progress, establish and improve the rules and indicator systems for the adjustment of the medical insurance drug catalog, and dynamically adjust and optimize the medical insurance drug catalog.
Drugs with high clinical value, obvious benefits to patients and excellent economic evaluation will be included in the scope of medical insurance payment in a timely manner according to procedures. Eligible Chinese medicines will be included in the scope of medical insurance payment in accordance with regulations. Improve the evaluation mechanism of medical insurance drugs, strengthen the monitoring of the landing of medical insurance drug lists and the evaluation of innovative drugs, support drug innovation, and improve the accessibility of negotiated drugs.
In general, under the implementation of the medical reform policy, it has brought opportunities and challenges to pharmaceutical people, which requires relevant pharmaceutical companies to adjust their positioning in order to better develop in the market.